Evidence map›Paper›PMID 22272218›Full record

ArticleTheranostics2012

Development of manganese-based nanoparticles as contrast probes for magnetic resonance imaging.

Zipeng Zhen, Jin Xie

Open access · goldAbstract read
In one paragraph

Article in Theranostics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 142 citations in OpenAlex.

  1. Article
  2. Review
  3. Aqueous-stable Mn(II)-MOF nanoparticles with highJournal of materials chemistry. B · 2025
    Article
  4. Neutron activation analysis of manganese in samples of human sternum.Journal of radioanalytical and nuclear chemistry · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Mn-Based MRI Contrast Agents: An Overview.Molecules (Basel, Switzerland) · 2023
    Review
  9. Article
  10. Nanomaterial-based contrast agents.Nature reviews. Methods primers · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Nanotechnology for Cancer Therapy Based on Chemotherapy.Molecules (Basel, Switzerland) · 2018
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Zipeng ZhenDepartment of Chemistry and Bio-Imaging Research Center (BIRC), University of Georgia, Athens, GA 30602.
Jin Xie
University of Georgia · US

Funding

Nanoplatform-based combinational therapy against breast cancer R00CA153772 · NCI · UNIVERSITY OF GEORGIA · PI XIE, JIN · 2011 to 2013
$710k
NCI NIH HHS R00 CA153772
6 · The paper itself

Abstract

MRI is one of the most important imaging tools in clinics. It interrogates nuclei of atoms in a living subject, providing detailed delineation with high spatial and temporal resolutions. To compensate the innate low sensitivity, MRI contrast probes were developed and widely used. These are typically paramagnetic or superparamagnetic materials, functioning by reducing relaxation times of nearby protons. Previously, gadolinium(Gd)-based T(1) contrast probes were dominantly used. However, it was found recently that their uses are occasionally associated with nephrogenic system fibrosis (NSF), which suggests a need of finding alternatives. Among the efforts, manganese-containing nanoparticles have attracted much attention. By careful engineering, manganese nanoparticles with comparable r(1) relaxivities can be yielded. Moreover, other functionalities, be a targeting motif, a therapeutic agent or a second imaging component, can be loaded onto these nanoparticles, resulting in multifunctional nanoplatforms.

Indexed as

contrast probesmanganeseMRInanomedicinenanoparticlestheranostics.tumor imaging

Identifiers

PMID22272218
PMCPMC3263515
OpenAlexW2106821617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.